The tractable pharmacokinetic properties of peptide‐based imaging agents also enable the quantification of target pharmacodynamics as we have shown for imaging programmed death‐ligand 1 (PD‐L1) expression in cancers.[25, 26] Notably, the application of low molecular weight agents for targeting CD38 in MM has not been previously reported. Here, CD38 is linked to Miyoshi myopathy.